Dynamic 68Ga-PSMA and 18F-FDG PET/CT scans before 177Lu-PSMA treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients with progressive metastatic castration‑resistant prostate cancer who have received taxane chemotherapy and at least one androgen‑receptor–targeted therapy undergo both dynamic 68Ga‑PSMA and 18F‑FDG PET/CT imaging prior to possible 177Lu‑PSMA treatment. The study uses parametric (dynamic) PET acquisition and kinetic analysis to compare tracer behavior across lesions and to detect FDG‑positive/PSMA‑negative sites associated with poorer prognosis. Investigators will compare dynamic parametric measures to standard imaging readouts to see if they improve lesion characterization and treatment selection. This single‑center study at Centre Henri Becquerel aims to inform which patients should be offered 177Lu‑PSMA therapy based on imaging biology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent.
* Progressive metastatic castration-resistant prostate adenocarcinoma, which has been treated with taxane chemotherapy and at least one anti-androgen hormone therapy.
* Evaluated by 18F-FDG and 68Ga-PSMA PET/CT prior to potential treatment with 177Lu-PSMA.
* Affiliated with or beneficiary of a social protection scheme.
* WHO stage 0 or 1.

Exclusion Criteria:

* Patients unable to understand the study for any reason or comply with the trial requirements (due to language barriers, psychological issues, geographical constraints, etc.).
* Patients unable to undergo the examinations and/or maintain a prolonged lying position (due to back pain, etc.).

Where it's running

• Centre Henri Becquerel
  Rouen, France Recruiting

Study contacts

• Study coordinator: Pierre Decazes, MD,PhD
• Email: pierre.decazes@chb.unicancer.fr
• Phone: +3276673059

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

• First-in-human testing of repeated autologous TIL immunotherapy for metastatic colorectal and prostate cancer

  This trial tests whether repeated infusions of a patient’s own tumor-infiltrating lymphocytes (TILs) can persist longer in the blood and help people with metastatic colorectal or prostate cancer.

  Recruiting Phase 1/2 CuraCell TX AB · Frankfurt · NCT07255664

• PSMA PET to predict treatment response in advanced prostate cancer

  This will test whether PSMA PET scans can help predict how advanced prostate cancer will respond to systemic treatments such as hormone therapy, chemotherapy, or PSMA-targeted radioligand therapy.

  Recruiting at 4 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy and 3 other locations · NCT07089550

• Treatment for advanced prostate cancer using Pluvicto

  This study is testing if a new treatment called Pluvicto can help men with advanced prostate cancer that has spread to their bones feel better and improve their quality of life.

  Recruiting Phase 2 Excel Diagnostics and Nuclear Oncology Center · Houston, Texas · NCT06972628

• 7-day water-only fasting for metastatic prostate cancer

  This study will test whether a 7-day water-only fast (with a ketogenic very low-calorie option) is safe and doable for people with metastatic prostate cancer.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06826924

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.